Ind-Swift Labs.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE915B01019
  • NSEID: INDSWFTLAB
  • BSEID: 532305
INR
360.35
-6.55 (-1.79%)
BSENSE

Oct 09

BSE+NSE Vol: 6.58 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Fredun Pharma
Shukra Pharma.
Kwality Pharma
Solara Active
Unichem Labs.
Aarti Drugs
Gufic BioScience
Ind-Swift Labs.
SMS Pharma.
Hikal
Advanced Enzyme
Why is Ind-Swift Laboratories Ltd ?
1
Weak Long Term Fundamental Strength with a -23.73% CAGR growth in Operating Profits over the last 5 years
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 1.68 times
  • The company has been able to generate a Return on Equity (avg) of 7.99% signifying low profitability per unit of shareholders funds
2
With a growth in Net Profit of 184.05%, the company declared Very Positive results in Jun 26
  • The company has declared positive results for the last 4 consecutive quarters
  • NET SALES(Q) Highest at Rs 191.45 cr
  • PBDIT(Q) Highest at Rs 33.43 cr.
  • OPERATING PROFIT TO NET SALES(Q) Highest at 17.46%
3
Stock is technically in a Bullish range
  • The technical trend has improved from Mildly Bullish on 01-Jun-26 and has generated 137% returns since then
  • Multiple factors for the stock are Bullish like MACD, KST, DOW and OBV
4
With ROE of 3.6, it has a Very Expensive valuation with a 2.3 Price to Book Value
  • The stock is trading at a fair value compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 265.47%, its profits have risen by 257.4% ; the PEG ratio of the company is 0.3
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Ind-Swift Labs. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Ind-Swift Labs. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Ind-Swift Labs.
251.15%
4.42
60.03%
Sensex
-11.8%
-0.48
13.44%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-6.51%
EBIT Growth (5y)
-23.73%
EBIT to Interest (avg)
7.43
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.31
Sales to Capital Employed (avg)
0.67
Tax Ratio
19.66%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
11.05%
ROCE (avg)
8.57%
ROE (avg)
7.99%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
48
Industry P/E
36
Price to Book Value
2.31
EV to EBIT
98.32
EV to EBITDA
46.38
EV to Capital Employed
2.88
EV to Sales
4.16
PEG Ratio
0.32
Dividend Yield
NA
ROCE (Latest)
-0.08%
ROE (Latest)
3.61%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bullish
Bullish
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

28What is working for the Company
NET SALES(Q)

Highest at Rs 191.45 cr

PBDIT(Q)

Highest at Rs 33.43 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 17.46%

PBT LESS OI(Q)

Highest at Rs 25.15 cr.

PAT(Q)

Highest at Rs 24.86 cr.

EPS(Q)

Highest at Rs 2.84

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Ind-Swift Labs.
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 25.15 cr has Grown at 694.56%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 24.86 cr has Grown at 183.5%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Quarterly
Highest at Rs 191.45 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Net Sales - Quarterly
At Rs 191.45 cr has Grown at 25.35%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 33.43 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 17.46%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 25.15 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 24.86 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 2.84
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)